Rahul Bhargava: Landmark Study Shows Excellent Outcomes in Pediatric AML Transplant
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care, posted on LinkedIn:
”Dr Vikas Dua makes Fortis Healthcare and India proud with its exceptional outcomes of Bone Marrow transplant in Pediatric AML
2nd biggest paper after sickle cell one
Proud Moment for FMRI Pediatric Hematology and BMT Team!
Our landmark study, “Excellent Outcomes of Hematopoietic Stem Cell Transplant for Pediatric High-Risk and Relapsed Acute Myeloid Leukemia,” has been published in the Journal of Pediatric Hematology/Oncology (JPHO)!
Study Highlights:
- Median age at transplant: 8.5 years
- Male : Female ratio: 1.9 : 1
- Total patients: 48 (46 de novo AML + 2 secondary AML)
- Donor types: 29 MSD | 3 MRD | 18 Haploidentical HSCT
- Conditioning regimen: Fludarabine-based (all engrafted)
- Cumulative relapse: 16 %
- Median follow-up: 40.9 months
- Event-Free Survival (EFS): 78 %
- Overall Survival (OS): 86 %
- Non-Relapse Mortality (NRM): 6 %
- Matched vs Haplo HSCT: EFS 78.1 % vs 77.8 % (p = 0.78); OS 84.4 % vs 88.9 % (p = 0.83)
These outcomes reaffirm that Haploidentical HSCT can achieve results comparable to matched donor transplants, expanding access to curative therapy for children with high-risk AML.
Heartfelt gratitude to Dr Vikas Dua dedicated physician-scientist making Fortis and India proud, and to the incredible team — Swati Bhayana, Arun Danewa Sohini, Dr Parminder, our nurse practitioners, Aastha Gupta, Dr. Neha Rastogi Panda, Shrinidhi Nathany, Amit Pal Singh Raina, Geetanjali Gupta for their remarkable work and perseverance.
Special congratulations to Sunisha Arora , our Associate Consultant, for leading this effort and getting it in black and white! Yashpal Singh Rawat, Dr Ritu Mittal Garg, Dr. Abhishek Sharma, Anusha S., Rachit Agrawal, Nikhil M Kumar.
You truly deserve a grand celebration!”

Stay updated with Hemostasis Today.
-
Feb 12, 2026, 11:52Miriam Mwachinga: Let’s Focus More on Rare Diseases and Their Impact on Quality of Life
-
Feb 12, 2026, 11:32Sophie Titoulet Announces Challenge Plasma 2026: The Art of Giving Regularly
-
Feb 12, 2026, 11:19Goran Mitulović: Proteomics and Mass Spectroscopy Identified The Cause of VITT
-
Feb 12, 2026, 11:14Leonardo Roever: CHR as a Composite Biomarker for Stroke Risk Stratification
-
Feb 12, 2026, 11:10Filippo Cademartiri: Can AI Reduce Diagnostic Errors in Low-Resource Settings?
-
Feb 12, 2026, 11:06Murad Ali: An Important Marker of Active Clot Formation and Fibrinolysis
-
Feb 12, 2026, 11:02Right Chukwuneme: Daltaparin vs Apixaban – Efficacy or Safety Paradox?
-
Feb 12, 2026, 10:57Muntadhar Al Moosawi Gives A Talk on Chromogenic FVIII in Hemophilia A at WHX Labs Dubai
-
Feb 12, 2026, 10:52Dario Bongiovanni: Meeting Wrap-Up of ESC Heart and Stroke and EuroThrombosis 2025